GTx, Inc. (GTXI), Novartis AG (ADR) (NVS): This Week in Biotech

Page 1 of 2

With the SPDR S&P Biotech Index up 37% over the trailing-12-month period, it’s evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let’s have a look at some of the rulings, studies, and companies that made waves in the sector last week.

As always, let’s start off with some of the positive stories we witnessed this week.

GTx, Inc. (NASDAQ:GTXI)

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) soared as much as 27% on Monday after announcing the approval of extended-release epilepsy drug, Trokendi XR, by the Food and Drug Administration. The clearly good news here is that Trokendi is approved in patients as young as six years of age, with Supernus being granted a waiver on certain pediatric study requirements. With Trokendi XR and Oxtellar XR now approved for the treatment of epilepsy, Supernus projects it’ll be breakeven on a cash flow basis by the end of next year. While certainly good news, quarterly losses will continue in the interim and, given that reality, shareholders wound up giving back nearly all of its early week gains by the end of the week.

In a similar instance of great news, Incyte Corporation (NASDAQ:INCY) shares skyrocketed after announcing positive proof-of-concept data from a phase 2a clinical study of ruxolitinib in cases of refractory metastatic pancreatic cancer. The data from the study in which ruxolitinib (the scientific name for Jakafi, Incyte’s FDA-approved myelofibrosis drug) was combined with Roche‘s Xeloda demonstrated six-month survival of 42% for the ruxolitinib arm as compared to just 11% for the placebo. In addition, only the ruxolitinib arm showed any durable tumor response and significant improvement in body weight.

Not to be lost on this news, either, is Novartis AG (ADR) (NYSE:NVS) which is the global licensing holder to ruxolitinib outside the United States. Novartis AG (ADR) (NYSE:NVS) recently lost patent exclusivity to its best-selling hypertensive drug, Diovan, and is definitely looking for ways to bolster its product pipeline. If ruxolitinib, a JAK1 and JAK 2 inhibitor, continues to show progress in trials, I wouldn’t be shocked to see Novartis AG (ADR) (NYSE:NVS) simply snatch up Incyte and keep 100% of sales. Shares of Incyte Corporation (NASDAQ:INCY) gained 30% this week while Novartis AG (ADR) (NYSE:NVS)’ shares added 4%.

Rounding out the good news this week with a solid gain of 20% was Pain Therapeutics, Inc. (NASDAQ:PTIE), which rallied after Pfizer announced that it would indeed be running another clinical trial for painkiller Remoxy. The Remoxy saga, which was developed by Pain Therapeutics, Inc. (NASDAQ:PTIE), is licensed to Pfizer and incorporates DURECT‘s gel-capsule technology, seems to be right up there next to Days of Our Lives for longest running daytime drama.

Page 1 of 2

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The World’s Most Famous Circuses

Best Hair Stylists

Most Popular NASCAR Drivers

The Best Romance Movies of all Time

The Most Wanted Drug Lords

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!